GetTopicDetailResponse(id=62ca1589862, topicName=Sarilumab, introduction=Sarilumab, content=null, image=null, comments=1, allHits=1703, url=https://h5.medsci.cn/topic?id=15898, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=11418, tagList=[TagDto(tagId=11418, tagName=Sarilumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=813406, encodeId=e21f81340610, content=重癥<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>患者使用<a href='/topic/show?id=62ca1589862' target=_blank style='color:#2F92EE;'>#Sarilumab#</a>治療的總體臨床改善率和死亡率與標(biāo)準(zhǔn)治療沒有顯著差異，這也可以推導(dǎo)出來<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠單抗#</a>（也是一種IL-6拮抗劑），應(yīng)該也不會有什么作用的。<a href='/topic/show?id=94111038205a' target=_blank style='color:#2F92EE;'>#炎癥因子風(fēng)暴#</a>的機(jī)制比較復(fù)雜，IL-6只是其中之一。, objectTitle=Ann Rheum Dis：重癥新冠肺炎炎癥風(fēng)暴使用sarilumab阻斷白介素-6的療效, objectType=article, longId=197867, objectId=26d719e867cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020721/1595300145989_1613704.jpg, objectUrl=/article/show_article.do?id=26d719e867cc, replyNumber=1, likeNumber=804, createdTime=2020-08-26, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d719e867cc, moduleTitle=Ann Rheum Dis：重癥新冠肺炎炎癥風(fēng)暴使用sarilumab阻斷白介素-6的療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=26d719e867cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
